{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:27Z","timestamp":1786982667198,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01431-0","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:19:16Z","timestamp":1747552756000},"page":"1973-1983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Persistent Psoriasis Lesions Using Calcipotriol\/Betamethasone Foam Combitherapy: Real-World Evidence Case Series from France"],"prefix":"10.1007","volume":"15","author":[{"given":"Marc","family":"Perrussel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2491-9654","authenticated-orcid":false,"given":"Zaruhi","family":"Arakelyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"key":"1431_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. IJMS. 2019;20:1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"IJMS"},{"key":"1431_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2147\/CCID.S180698","volume":"11","author":"A Pinter","year":"2018","unstructured":"Pinter A, Thormann H, Angeletti F, Jalili A. Calcipotriol\/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. CCID. 2018;11:451\u20139. https:\/\/doi.org\/10.2147\/CCID.S180698.","journal-title":"CCID"},{"key":"1431_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.15340","volume":"33","author":"F Amatore","year":"2019","unstructured":"Amatore F, Villani A-P, Tauber M, Viguier M, Guillot B, the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33:464\u201383. https:\/\/doi.org\/10.1111\/jdv.15340.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1431_CR4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/life11111151","volume":"11","author":"N Kirsten","year":"2021","unstructured":"Kirsten N, Rustenbach S, Von Kiedrowski R, Sorbe C, Reich K, Augustin M. Which PASI outcome is most relevant to the patients in real-world care? Life. 2021;11:1151. https:\/\/doi.org\/10.3390\/life11111151.","journal-title":"Life"},{"key":"1431_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2020.5362","volume":"157","author":"T Morrison","year":"2021","unstructured":"Morrison T, Johnson J, Baghoomian W, Hamilton A, Simpson E, Greiling T, et al. Shared decision-making in dermatology: a scoping review. JAMA Dermatol. 2021;157:330. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5362.","journal-title":"JAMA Dermatol"},{"key":"1431_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jaad.2023.03.039","volume":"89","author":"D Yee","year":"2023","unstructured":"Yee D, Kingston P, Lee K, Huang M, Peterson H, Korouri E, et al. Shared decision-making and satisfaction with care in patients with psoriasis: a population-based study in the United States. J Am Acad Dermatol. 2023;89:920\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2023.03.039.","journal-title":"J Am Acad Dermatol"},{"key":"1431_CR7","first-page":"26","volume":"8","author":"T Finch","year":"2015","unstructured":"Finch T, Shim TN, Roberts L, Johnson O. Treatment satisfaction among patients with moderate-to-severe psoriasis. J Clin Aesthet Dermatol. 2015;8:26\u201330.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1431_CR8","doi-asserted-by":"publisher","DOI":"10.5070\/D3222030081","author":"N Korman","year":"2016","unstructured":"Korman N, Zhao Y, Pike J, Roberts J, Sullivan E. Patient satisfaction with current psoriasis treatment: a real-world study in the USA. Dermatol Online J. 2016. https:\/\/doi.org\/10.5070\/D3222030081.","journal-title":"Dermatol Online J"},{"key":"1431_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD\u2013NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"key":"1431_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/jdv.13859","volume":"31","author":"C Paul","year":"2017","unstructured":"Paul C, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Bang B, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. Acad Dermatol Venereol. 2017;31:119\u201326. https:\/\/doi.org\/10.1111\/jdv.13859.","journal-title":"Acad Dermatol Venereol"},{"key":"1431_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaad.2020.09.037","volume":"84","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl M, Kircik L, Lacour J-P, Liljedahl M, Lynde C, M\u00f8rch MH, et al. Twice-weekly topical calcipotriene\/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84:1269\u201377. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.037.","journal-title":"J Am Acad Dermatol"},{"key":"1431_CR12","first-page":"1468","volume":"14","author":"C Leonardi","year":"2015","unstructured":"Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris\u2014a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14:1468\u201377.","journal-title":"J Drugs Dermatol"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/1346-8138.16867","volume":"50","author":"Y Hou","year":"2023","unstructured":"Hou Y, Lin S. Real-world efficacy of adjunctive calcipotriene\/betamethasone dipropionate foam for recalcitrant psoriatic lesions on the scalp or lower legs with biologic therapy. J Dermatol. 2023;50:1272\u20138. https:\/\/doi.org\/10.1111\/1346-8138.16867.","journal-title":"J Dermatol"},{"key":"1431_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.36849\/JDD.2020.10.36849\/JDD.2020.5020","volume":"19","author":"LH Kircik","year":"2020","unstructured":"Kircik LH, Schlesinger TE, Tanghetti E. Efficacy and safety of calcipotriene 0.005%\/betamethasone dipropionate 0.064% foam with apremilast for moderate plaque psoriasis. J Drugs Dermatol. 2020;19:874\u201380. https:\/\/doi.org\/10.36849\/JDD.2020.10.36849\/JDD.2020.5020.","journal-title":"J Drugs Dermatol"},{"key":"1431_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s13555-020-00454-z","volume":"10","author":"J Bagel","year":"2020","unstructured":"Bagel J, Nelson E, Zapata J, Hetzel A. Adjunctive use of calcipotriene\/betamethasone dipropionate foam in a real-world setting curtails the cost of biologics without reducing efficacy in psoriasis. Dermatol Ther (Heidelb). 2020;10:1383\u201396. https:\/\/doi.org\/10.1007\/s13555-020-00454-z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1431_CR16","unstructured":"IQVIA. Treatment Satisfaction Questionnaire for Medication (TSQM). https:\/\/www.iqvia.com\/solutions\/research-and-development\/consulting\/patient-centered-endpoints\/clinical-outcome-assessments-coa\/tsqm. Accessed 8 April 2025."},{"key":"1431_CR17","unstructured":"Republique Francaise. LOI n\u00b0 2012\u2013300 du 5 mars 2012 relative aux recherches impliquant la personne humaine (1). legifrance.gouv.fr 2016. https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000025441587\/. Accessed 8 April 2025."},{"key":"1431_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","volume":"2","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2:38\u201343. https:\/\/doi.org\/10.7453\/gahmj.2013.008.","journal-title":"Glob Adv Health Med"},{"key":"1431_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"key":"1431_CR20","first-page":"36","volume":"26","author":"MEG Sison","year":"2017","unstructured":"Sison MEG, Sumilanc FM, Frez M, Lorna F. Combination therapy versus monotherapy for moderate to severe chronic plaque psoriasis in adults. J Philippine Dermatol Soc. 2017;26:36\u201345.","journal-title":"J Philippine Dermatol Soc"},{"key":"1431_CR21","doi-asserted-by":"publisher","first-page":"2200570","DOI":"10.1080\/09546634.2023.2200570","volume":"34","author":"N Ninosu","year":"2023","unstructured":"Ninosu N, Hoelker S, Kappenstein M, Buettner S, Peitsch WK, Schaarschmidt M-L. Treatment satisfaction of patients with psoriasis with topical therapy in a real-world setting: unmet need for higher effectiveness. J Dermatol Treat. 2023;34:2200570. https:\/\/doi.org\/10.1080\/09546634.2023.2200570.","journal-title":"J Dermatol Treat"},{"key":"1431_CR22","doi-asserted-by":"publisher","first-page":"1759720X2412740","DOI":"10.1177\/1759720X241274055","volume":"16","author":"E Skouvaklidou","year":"2024","unstructured":"Skouvaklidou E, Avgerou P, Vassilakis KD, Fragoulis GE, Kougkas N. Monotherapy or combination therapy in PsA: current aspects. Ther Adv Musculoskelet. 2024;16:1759720X241274055. https:\/\/doi.org\/10.1177\/1759720X241274055.","journal-title":"Ther Adv Musculoskelet"},{"key":"1431_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jdv.17673","volume":"36","author":"A Jalili","year":"2022","unstructured":"Jalili A, Calzavara-Pinton P, Kircik L, Lons-Danic D, Pink A, Tyring S, et al. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal\/BD foam: a post-hoc analysis of PSO-LONG. Acad Dermatol Venereol. 2022;36:60\u20137. https:\/\/doi.org\/10.1111\/jdv.17673.","journal-title":"Acad Dermatol Venereol"},{"key":"1431_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jdv.15393","volume":"33","author":"A Jalili","year":"2019","unstructured":"Jalili A, Lebwohl M, Stein Gold L, Andersen SB, Jensen KL, Pink AE, et al. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. Acad Dermatol Venereol. 2019;33:709\u201317. https:\/\/doi.org\/10.1111\/jdv.15393.","journal-title":"Acad Dermatol Venereol"},{"key":"1431_CR25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/jdv.18053","volume":"36","author":"L Guenther","year":"2022","unstructured":"Guenther L, Takhar A, Megna M, Sebastian M, Nyholm N, Thoning H, et al. Impact of fixed-dose combination Cal\/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind. PSO-LONG trial Acad Dermatol Venereol. 2022;36:1054\u201363. https:\/\/doi.org\/10.1111\/jdv.18053.","journal-title":"PSO-LONG trial Acad Dermatol Venereol"},{"key":"1431_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jdv.17084","volume":"35","author":"A Armstrong","year":"2021","unstructured":"Armstrong A, Gerdes S. Calcipotriol\/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective. Acad Dermatol Venereol. 2021;35:28\u201334. https:\/\/doi.org\/10.1111\/jdv.17084.","journal-title":"Acad Dermatol Venereol"},{"key":"1431_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15077","volume":"34","author":"A Campanati","year":"2021","unstructured":"Campanati A, Atzori L, Potenza C, Damiani G, Bianchi L, Corazza M, et al. Patient satisfaction with calcipotriol\/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study. Dermatol Ther. 2021;34: e15077. https:\/\/doi.org\/10.1111\/dth.15077.","journal-title":"Dermatol Ther"},{"key":"1431_CR28","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ad.2019.03.013","volume":"110","author":"M Velasco","year":"2019","unstructured":"Velasco M, Gonz\u00e1lez-Fern\u00e1ndez D, Rodriguez-Mart\u00edn M, S\u00e1nchez-Rega\u00f1a M, P\u00e9rez-Barrio S. Satisfacci\u00f3n del paciente y el m\u00e9dico con la espuma en aerosol de calcipotriol y dipropionato de betametasona para el tratamiento de la psoriasis vulgar en el cuerpo. Actas Dermosifiliogr. 2019;110:752\u20138. https:\/\/doi.org\/10.1016\/j.ad.2019.03.013.","journal-title":"Actas Dermosifiliogr"},{"key":"1431_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2340\/00015555-2011","volume":"95","author":"M Schaarschmidt","year":"2015","unstructured":"Schaarschmidt M, Kromer C, Herr R, Schmieder A, Goerdt S, Peitsch W. Treatment satisfaction of patients with psoriasis. Acta Derm Venerol. 2015;95:572\u20138. https:\/\/doi.org\/10.2340\/00015555-2011.","journal-title":"Acta Derm Venerol"},{"key":"1431_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s13555-021-00501-3","volume":"11","author":"R Aschoff","year":"2021","unstructured":"Aschoff R, Martorell A, Anger T, Chayer D, Bewley A. Real-world experience using topical therapy\u2014calcipotriol and betamethasone dipropionate foam in adults with beyond-mild psoriasis. Dermatol Ther (Heidelb). 2021;11:555\u201369. https:\/\/doi.org\/10.1007\/s13555-021-00501-3.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01431-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01431-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01431-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T06:00:06Z","timestamp":1748671206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01431-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01431-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Marc Perrussel has previously been provided with financial assistance by Abbott, Abbvie, AMGEN, BMS, Celg\u00e8ne, Genevrier, Lilly, Janssen, LEOPharma, Merck-Serono, Novartis, Sanofi, Schering-Plough, UCB, and Wyeth-Pfizer. Dr Zaruhi Arakelyan has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval by an institutional review board was not applicable to this study according to French legislation. All patients in this manuscript have given oral informed consent for participation in the case series and the use of their deidentified, anonymized, aggregated data and their case details for publication. Local governance procedures, including the collection and storage of non-identifiable patient data, were followed and adhered to. The research was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}